References
- Ahn C (1998). An evaluation of phase I cancer clinical trial designs, Statistics in Medicine, 17, 1537-1549.
- Dixon WJ and Mood AM (1948). A method for obtaining and analyzing sensitivity data, Journal of the American Statistical Association, 43, 109-126.
- Faries D (1994). Practical modifications of the continual reassessment method for phase i cancer clinical trials, Journal of Biopharmaceutical Statistics, 4, 147-164.
- Garrett-Mayer E (2006). The continual reassessment method for dose-finding studies: A tutorial, Clinical Trials, 3, 57-71.
- Goodman SN, Zahurak ML, and Piantadosi S (1995). Some practical improvements in the continual reassessment method for phase I studies, Statistics in Medicine, 14, 1149-1161.
- Guo W, Wang SJ, Yang S, Lynn H, and Ji Y (2017). A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2, Contemporary Clinical Trials, 58, 23-33.
- He W, Liu J, Binkowitz B, and Quan H (2006). A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials, Statistics in Medicine, 25, 2027-2042.
- Heyd JM and Carlin BP (1999). Adaptive design improvements in the continual reassessment method for phase I studies, Statistics in Medicine, 18, 1307-1321.
- Jang E and Kim D (2014). Maximum tolerated dose estimation with dose de-escalation design in a phase I clinical trials, The Korean Journal of Applied Statistics, 27, 1115-1123.
- Ji Y, Liu P, Li Y, and Nebiyou Bekele B (2010). A modified toxicity probability interval method for dose-finding trials, Clinical Trials, 7, 653-663.
- Ji Y and Wang SJ (2013). Modified toxicity probability interval design: A safer and more reliable method than the 3 + 3 design for practical phase I trials, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 1785.
- Kang SH (2002). Investigation on the modified continual reassessment method in phase I clinical trial, The Korean of Applied Statistics, 15, 323-336.
- Kwon D and Kim D (2019). Maximum tolerated dose estimation using continual reassessment method in phase I clinical trial, The Korean Journal of Applied Statistics, 32, 741-752.
- Lee NM and Kim DJ (2012). Two-stage maximum tolerated dose estimation by stopping rule in a phase I clinical trial, The Korean Journal of Applied Statistics, 19, 57-64.
- Lee JH and Song HH (2011). Continual reassessment method in phase I clinical trials for Leukemia patients, The Korean Journal of Applied Statistics, 18, 581-594.
- Leung E, Crass RL, Jorgensen SC, Raybardhan S, Langford BJ, Moore WJ, and Rhodes NJ (2022). Pharmacokinetic/pharmacodynamic considerations of alternate dosing strategies of tocilizumab in COVID-19, Clinical Pharmacokinetics, 61, 155-165.
- Liu S and Yuan Y (2015). Bayesian optimal interval designs for phase I clinical trials, Journal of the Royal Statistical Society: Series C: Applied Statistics, 64, 507-523.
- O'Quigley J, Pepe M, and Fisher L (1990). Continual reassessment method: A practical design for phase 1 clinical trials in cancer, Biometrics, 46, 33-48.
- O'Quigley J and Shen LZ (1996). Continual reassessment method: A likelihood approach, Biometrics, 52, 673-684.
- O'Quigley J and Zohar S (2006). Experimental designs for phase I and phase I/II dose-finding studies, British Journal of Cancer, 94, 609-613.
- Park SJ, Kim Y, and Choi S (2021). A comparative study on the accuracy and safety of Bayesian CRM-Based MTD estimation method, The Korean Data and Information Science Society, 32, 337-350.
- Storer BE (1989). Design and analysis of phase I clinical trials, Biometrics, 45, 925-937.
- Tank A, Peterson HM, Pera V, Tabassum S, Leproux A, O'Sullivan T, and Roblyer D (2020). Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens, Breast Cancer Research, 22, 1-10.
- Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, and Kashour T (2021). Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis, Clinical Microbiology and Infection, 27, 215-227.
- Yan F, Mandrekar SJ, and Yuan Y (2017). Keyboard: A novel Bayesian toxicity probability interval design for phase I clinical trials, Clinical Cancer Research, 23, 3994-4003.
- Yuan Y, Hess KR, Hilsenbeck SG, and Gilbert MR (2016). Bayesian optimal interval design: A simple and well-performing design for phase I oncology trials, Clinical Cancer Research, 22, 4291-4301.
- Zhu Y, Hwang WT, and Li Y (2019). Evaluating the effects of design parameters on the performances of phase I trial designs, Contemporary Clinical Trials Communications, 15, 100379.